Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026
As of the close of play on February 12, consensus sentiment around Spyre Therapeutics (NASDAQ:SYRE) was strongly bullish.
Spyre Therapeutics Inc. (SYRE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Siren L.L.C. Raymond Debbane | 818,598 | $26,817,270 | +123% | 0.8% |
| 2. | SilverArc Capital Devesh Gandhi | 187,737 | $6,150,264 | 0.85% | |
| 3. | Neo Ivy Capital Renee Yao | 18,261 | $598,230 | 0.09% | |
| 4. | Arrowpoint Investment Partners Jonathan Xiong And Joo Lee | 13,724 | $449,598 | 0.07% | |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.56 | 90,000 | $50,472.00 | 90,000 | 2022-08-25 | Filing | |
| $0.71 | 28,200 | $20,022.00 | 36,200 | 2022-06-08 | Filing | |
| $2.34 | 80,079 | $187,705.18 | 550,540 | 2022-03-16 | Filing | |
| $1.86 | 42,417 | $78,942.28 | 473,461 | 2022-03-15 | Filing | |
| $1.93 | 67,472 | $130,220.96 | 431,044 | 2022-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.87 | 14,043 | $461,593.41 | 657,540 | 2026-02-02 | Filing | |
| $31.82 | 957 | $30,451.74 | 671,583 | 2026-02-02 | Filing | |
| $32.39 | 100 | $3,239.00 | 671,907 | 2026-01-02 | Filing | |
| $31.79 | 2,191 | $69,651.89 | 672,007 | 2026-01-02 | Filing | |
| $30.47 | 12,709 | $387,243.23 | 674,198 | 2026-01-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,522,101 | $180,904,030 | 0% | |
| 2. | 4,035,074 | $132,189,024 | 0% | |
| 3. | 3,492,541 | $114,415,643 | 0.02% | |
| 4. | 2,262,839 | $74,130,606 | 0% | |
| 5. | 1,659,140 | $54,362,088 | 0% |
News See All
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating
The update follows Mizuho’s initiation of coverage on the stock on December 18 with an Outperform rating and a share price target of $53, where it cited potential in the company’s pipeline of anti...
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
10 Hottest Small Cap Stocks to Buy Now
On November 12, Scott Chronert, Citi's U.S. equity strategist, appeared on a CNBC Television interview to discuss his bullish case for small- and mid-cap stocks.
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial
On September 15, 2025, Spyre Therapeutics Inc. (NASDAQ:SYRE) announced the enrollment of the first patient in its Phase 2 SKYWAY trial targeting multiple autoimmune diseases.
10 Best Debt Free Small Cap Stocks to Buy Now
High leverage can be both an advantage and a liability.
Hedge Fund Resource Center Billionaire Hedge Funds
